Lack of effect of citalopram on magnetic resonance spectroscopy
                    measures of glutamate and glutamine in frontal cortex of healthy
                volunteers by Taylor, MJ et al.
Lack of effect of citalopram on magnetic
resonance spectroscopy measures of
glutamate and glutamine in frontal
cortex of healthy volunteers
MJ Taylor Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom.
R Norbury Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom.
S Murphy Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom.
S Rudebeck Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom.
P Jezzard The Centre for Functional Magnetic Resonance Imaging of the Brain, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
PJ Cowen Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, United Kingdom.
Abstract
Magnetic resonance spectroscopy (MRS) is a non-invasive imaging
technique that can provide localised measures of brain chemistry in vivo.
We previously found that healthy volunteers receiving the selective
serotonin reuptake inhibitor, citalopram, daily for 1 week showed higher
levels of a combined measure of glutamate and glutamine (Glx) in
occipital cortex than those receiving placebo. The aim of this study was to
assess if a similar effect could be detected in the frontal brain region.
Twenty-three healthy volunteers randomised to receive either citalopram
20 mg or a placebo capsule daily for 7–10 days were studied and scanned
using a 3T Varian INOVA system before and at the end of treatment.
Standard short-TE (echo time) PRESS (Point-resolved spectroscopy)
(TE = 26 ms) and PRESS-J spectra were acquired from a single 8-cm3 voxel
in a frontal region incorporating anterior cingulate cortex. Glutamate and
total Glx levels were quantified both relative to creatine and as absolute
levels. Relative to placebo, citalopram produced no change in Glx or
glutamate alone at the end of the study. Similarly, no effect was seen on
other MRS measures studied: myo-inositol, choline, N-acetylaspartate and
creatine. These data suggest that the effects of serotonin reuptake to
modify cortical glutamatergic MRS measures may be regionally specific.
This supports the potential for MRS in assessing neuroanatomically specific
serotonin-glutamate interactions in the human brain.
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Introduction
Proton magnetic resonance spectroscopy (MRS) is an imaging
technique providing safe and non-invasive measurements
of aspects of brain chemistry. A range of measures can be
obtained including glutamate and the related compound, gluta-
mine. At the field strengths generally available for use in
human studies (up to 3 Tesla), reliably separating the MRS sig-
nals from glutamate and glutamine is challenging, so the com-
bined level of both glutamate and glutamine (Glx) is often
reported (Malhi, et al., 2002).
One of the most consistent findings in MRS studies of
acute major depressive disorder is lower Glx levels in frontal
brain regions (Auer, et al., 2000; Hasler, et al., 2007; Yildiz-
Yesiloglu and Ankerst, 2006). Glutamate released into the
extracellular space during neurotransmission is rapidly taken
up by astrocytes and converted to glutamine which can
be safely transported back to neurons (Danbolt, 2001). This
glutamate-glutamine cycle is a major component of brain ener-
getics (Hyder, et al., 2006). The reduced levels of Glx suggest
some abnormality of this glutamate-glutamine cycle is present
during the depressive episodes. Interestingly, it appears that
Glx levels in this region return to normal with full clinical
recovery (Bhagwagar, et al., 2008; Hasler, et al., 2005).
Serotonergic agents used in the treatment of depression,
such as the selective serotonin reuptake inhibitors (SSRIs), are
well placed to modify this glutamate-glutamine cycle, either by
actions on neuronal populations to modify the glutamate
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The Author(s), 2010.release or by modulating the astrocyte activity. Serotonergic
projections extend throughout cortex (Hornung, 2003), and
serotonin receptors are found on both neuronal and astrocyte
populations (Eastwood, et al., 2001; Jakab and Goldman-
Rakic, 1998, 2000).
Recently, we reported that 1 week of citalopram administra-
tion at a standard clinical dose was associated with an increase
in Glx levels in a posterior cortical region in healthy volunteers
(Taylor, et al., 2008). The aim of this study was to assess
whether a similar finding could be detected in the frontal cor-
tex. In addition, we also used an additional MRS technique,
PRESS-J, which permits the measurement of glutamate with-
out glutamine at moderate field strengths (Hurd, et al., 2004).
Materials and methods
Design
We studied 23 healthy volunteers (11 male, 12 female; mean
age 23 years, range 19–32) who were free of any axis I diagno-
sis assessed using the Standardised Clinical Interview for Diag-
nostic and Statistical Manual of Mental Disorders-IV (First,
et al., 1997) and had received no psychoactive medications for
at least 3 months before commencing the study. They were also
free of any physical illness and taking no medications except
the oral contraceptive pill. Participants were randomly assigned
to receive either citalopram 20 mg or placebo daily for 7–
10 days (the variable time of treatment was necessary to allow
for scanner availability). Magnetic resonance imaging (MRI)
was performed in the afternoon before starting medication
(day 0) and on the day of the final capsule (typically day 7,
but day 10 for three participants). Baseline and endpoint men-
tal states and personality traits were assessed by questionnaires
(Beck Depression Inventory, Spielberger State Anxiety Inven-
tory and the Positive and Negative Affect Scale).
Spectroscopy data were acquired using a 3T Varian INOVA
system with a head optimised gradient coil (Tesla Engineering,
Storrington, West Sussex, UK) and a head-only transmit/
receive quadrature birdcage radiofrequency coil. Data were
acquired from a 20 × 20 × 20 mm voxel placed in medial pre-
frontal cortex anterior to the genu of the corpus callosum
(Figure 1). The voxel was positioned manually by reference to
an axial T1-weighted gradient-echo image. PRESS data
(Bottomley, 1987) with (TE 26 ms, TR 3 s, averages = 64) and
without (TE 26 ms, TR 3 s, averages = 1) water suppressions
were acquired. PRESS-J data (Hurd, et al., 2004) with and
without water suppressions were similarly acquired with TE
arrayed from 35 to 195 ms in 10 ms increments (water-
suppressed data, total acquisitions = 128; non-water suppressed
data, total acquisitions = 16; TR = 3 s). T1-weighted structural
images of whole brain were acquired (2 mm3 voxel size). A
higher resolution structural image was acquired on a separate
occasion using a 1.5 T Siemens Sonata (Siemens, Camberley,
UK) scanner using a Turbo FLASH sequence (TR 12 ms, TE
5.65 ms, voxel size = 1 mm3).
MRS analyses
PRESS data were analysed with LCModel (Stephen
Provencher Inc., Oakville, Ontario, Canada) (Provencher,
1993), using the non-water suppressed data for eddy current
correction, calculating the metabolite concentrations relative
to creatine in conventional fashion using 15 metabolite basis
spectra and simulated lipid and macromolecule components.
PRESS-J data were pre-processed by zero-order phase correc-
tion, apodisation with a 5 Hz Gaussian filter and summing of
the 16 constituent spectra before analysis. Analysis of the
PRESS-J data used Advanced Method for Accurate, Robust,
and Efﬁcient Spectral ﬁtting (AMARES) (Vanhamme, et al.,
1997) since metabolite basis spectra were not available for
PRESS-J acquisitions, and the spectral simplification and flat
baselines obtained with this technique in vivo make direct single
peak fitting reliable (Hurd, et al., 2004).
Voxel composition
FMRIB Software Library (University of Oxford, Oxford,
UK) FMRIB Automated Segmentation Tool (Zhang, et al.,
2001) was used to segment the high-resolution structural
brain images into grey matter, white matter and
cerebrospinal fluid (CSF), to allow estimation of voxel
composition.
Figure 1 (A) Frontal voxel positioned to include pregenual cingulate
cortex (Brodmann areas 24 and 32). (B) Sample PRESS spectrum (echo
time 26 ms). (C) Sample PRESS-J spectrum. The PRESS-J spectrum
resembles standard PRESS with similar peaks for N-acetylaspartate (NAA),
choline (Cho), myo-inositol (mI) and creatine (Cr). However, the Glx
doublet is replaced by a singlet glutamate (Glu) peak at 2.35 ppm.
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The spectroscopy analyses using LCModel and AMARES
yielded estimates of concentration relative to creatine. A level
referenced to tissue water was also obtained for each measure
by correcting for voxel creatine levels (Barker, et al., 1993).
PRESS-J data were used to estimate both creatine and water
levels at t = 0, that is, without effects of T2 decay. Since simply
referencing to internal tissue water has been found to underes-
timate concentrations (Brooks, et al., 1999), the values refer-
enced to tissue water were corrected for voxel CSF content
and for differences in fractional grey and white matter water
density (Lentner, 1981) to provide an estimate of absolute
levels. In the absence of an external reference water standard,
these are reported in arbitrary units.
Statistical analyses
Results were analysed using the general linear model with time
(pre- and post-treatments) as the within subjects factor and
group (placebo vs citalopram) as between subjects factor. For
technical reasons, full data sets were not available for four par-
ticipants. Sensitivity analyses were performed for the effect of
including additional factors (gender) and covariates (age, dif-
ference in grey matter, white matter and CSF) in the model.
Correlations were calculated as Pearson’s product-moment
correlation coefficient (r2). Repeatability coefficients and
coefficients of variation for data from the placebo group were
calculated. Statistical analyses were performed in R (R Foun-
dation for Statistical Computing, Vienna, Austria) (version 2.5)
and SPSS (SPSS Inc., Chicago, IL, USA) (version 15).
Results
Participants
Of the 23 participants, 13 received citalopram and 10 received
placebo. The groups did not differ in baseline scores of anxiety
and depression, days of treatment, or post-treatment mood or
anxiety (Table 1).
Voxel characteristics
The spectroscopy data acquired were from a medial prefrontal
voxel incorporating pregenual cingulate cortex (Brodmann
areas 24 and 32; Figure 1). The voxel composition did not dif-
fer between groups or between sessions, and on average, it con-
tained 73% grey matter, 15% white matter and 12% CSF.
MRS results
There was no significant effect of treatment on any of the MRS
measures studied. No main effect of group or time, or
group × time interactions were found on analyses of Glx, glu-
tamate, myo-inositol, choline, N-acetylaspartate or creatine
whether concentrations were expressed relative to creatine or
as absolute concentrations (Figure 2).
Measures of Glx and glutamate showed good repeatability
across sessions, with mean coefficients of variation of 5.3 and
6.8% for levels relative to creatine and 6.8 and 7.4% referenced
to tissue water, with repeatability coefficients from 0.18 to 0.25.
Some correlation between Glx and glutamate measures was
observed (r2 = 0.22 with creatine referencing and r2 = 0.25
with water referencing, P < 0.05 in both cases).
Effect of composition on metabolite levels
For estimates of concentrations relative to creatine, voxel white
matter content was correlated with myo-inositol (r2 = 0.33,
P < 0.05) and inversely correlated with Glx (r2 = 0.31,
P < 0.05). For absolute concentration estimates, the inverse
correlation of Glx with white matter content remained
(r2 = 0.4, P < 0.05).
Discussion
The main finding of this study was an absence of effect of
1 week’s citalopram on MRS measures of glutamate and Glx
in anterior cingulate cortex in healthy volunteers. This was the
case whether concentrations were expressed relative to creatine
or as absolute levels.
This lack of effect seems unlikely to be simply explained by
the short duration of anti-depressant administration. Although
courses of anti-depressant treatment typically last for extended
periods, clinical trial data indicate that the beneficial effects of
SSRIs relative to placebo in the treatment of depression can be
detected after only 1 week (Taylor, et al., 2006). Also in healthy
volunteers, 1 week of citalopram is associated with consistent
Table 1 Group characteristics
Citalopram (n = 13) Placebo (n = 10)
Age 23 (3) 24 (3)
Gender 5 female, 8 male 7 female, 3 male
Beck Depression Inventory
Start 1.5 (1.7) 1.8 (2.3)
Endpoint 1.5 (2.1) 1.4 (2.1)
Positive and Negative Affect Scale (positive)
Start 35.7 (6.9) 37.5 (6.9)
Endpoint 31.0 (7.2) 36.8 (6.8)
Positive and Negative Affect Scale (negative)
Start 13.7 (6.7) 11.1 (1.6)
Endpoint 13.1 (4.8) 10.2 (0.4)
Spielberger State Anxiety Inventory
Start 32 (10.9) 28 (8.2)
Endpoint 33 (11.0) 26 (6.5)
Means with standard deviations. No significant differences between
groups.
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(Harmer, et al., 2004), and functional MRI reveals associated
changes in neural activity in regions including prefrontal cortex
(Harmer, et al., 2006). Furthermore, our previous data suggest
that the intervention used here increases Glx in occipito-parietal
cortex in healthy volunteers (Taylor, et al., 2008).
The use of the PRESS-J technique enabled us to measure
both glutamate and Glx in this study, but no effect of citalo-
pram on either measure was seen. Glutamine levels were not
measured directly, but in the absence of changes in glutamate,
altered glutamine would be reflected in changed Glx levels.
Therefore, these data suggest that there was no reliable change
in glutamine levels. Glx estimates sometimes contain a compo-
nent attributable to γ-aminobutryic acid (GABA) (Sanacora,
et al., 2008), and SSRI treatments in healthy subjects can
alter GABA levels. However, the magnitude of changes in
GABA that might be expected (Bhagwagar, et al., 2004;
Taylor, et al., 2008) would only change Glx estimates by a
few percent, which this study lacks the power to detect. Studies
using specific sequences to measure GABA would be required
to clarify this point (Mescher, et al., 1998).
The regional differences, in effect of citalopram, with
increased Glx evident in occipital region (Taylor, et al., 2008)
but not in the anterior cingulate in this study complement a
regional pattern of glutamatergic abnormalities in depression
and after recovery. Although acute depression is associated
with lowered Glx in anterior cingulate cortex (Auer, et al.,
2000; Hasler, et al., 2007; Pfleiderer, et al., 2003) and dorsolat-
eral prefrontal cortex (Michael, et al., 2003), increased gluta-
mate is reported in occipital cortex (Sanacora, et al., 2004).
After recovery, increased Glx is found in occipital cortex
(Bhagwagar, et al., 2007), whereas levels are normalised in
anterior cingulate (Bhagwagar, et al., 2008; Hasler, et al.,
2005). Taken together, it is possible that MRS identifies
region-specific effects of serotonin reuptake inhibitors on gluta-
matergic function. The functional significance of this pattern
of serotonin-glutamate interactions effects remains to be
elucidated.
Finally, it is worth noting that although no change in levels
of MRS Glx or glutamate were detected following citalopram
treatment in this study, it is certainly possible that citalopram
might induce more subtle changes in glutamate-glutamine
cycling which would not be detected by the present methodol-
ogy. For example, proton MRS does not provide a specific
measure of synaptic glutamate levels and changes in glutamate
release within neurotransmission might be masked by compen-
satory changes elsewhere. As noted in the Introduction section,
the process of glutamate-glutamine cycling is very important in
regulating brain neuronal activity and conceivably might be a
target for psychotropic drug treatment. However, to study such
effects, it will be necessary to use advanced MRS techniques,
such as carbon-13 MRS (Shen, et al., 1999).
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